Skip to content

Ketamine for depression: all studies

Page 126 of 178: studies 1,251 to 1,260 of 1,775, newest first. Back to the ketamine for depression overview

Research

What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide?

Frontiers in Psychiatry 2022 Mark A Gillman

Medication dosages are crucial-no single dose fits all. My paper compares the safety, scientific and practical applicability of fixed 25-50% concentrations of nitrous oxide (N2O) with the variable titrated concentrations of Psychotropic Analgesic N2O (PAN), as used in dentistry, and neuropsychiatry. A crucial difference is that PAN is always titrated, via an open circuit (nasal mask), to the...

Corrigendum: A cohort-based case report: The impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression.

Frontiers in Psychiatry 2022 Shannon Dames, Pamela Kryskow, Crosbie Watler correction

Corrigendum: A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers with PTSD and DepressionError in Figure/TableIn the published article, there was an error in Figure 2 as published. The PTSD label on the legend that is imbedded in the figure was on the legend component of the figure was posted on the anxiety...

Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder.

Frontiers in Psychiatry 2022 Joshua Willms, Ben McCauley, Lindsay Kerr et al.

Suicide is the most common cause of death in male resident physicians and the second most common cause of death in resident physicians overall. Physicians also experience high rates of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and burnout. These conditions frequently develop during medical school, and threaten not only physicians but the patients they care for. A...

DOI: 10.3389/fpsyt.2022.1020214 (opens in new tab) Full text (opens in new tab) Depression Ketamine assisted psychotherapy Medical school Suicidality

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.

Journal of Affective Disorders 2022 L. Mcinnes, Jimmy J Qian, Rishab Gargeya et al. 60 citations

BACKGROUND Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated. We set out to quantify treatment response to KIT in a large sample of patients from community-based practices. METHODS We retrospectively analyzed 9016 depression patients who received KIT between 2016 and 2020 at one of 178 community practices across the United...

Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.

Biochemical and Biophysical Research Communications 2022 Ya-Ting Wang, Ning-Ning Zhang, Ling Liu et al. 47 citations

PURPOSE OF REVIEW To explore the convergent downstream pathways of ketamine and rapastinel and drive further development of identification for following generational rapid-acting antidepressants in the synaptic process. RECENT FINDINGS Ketamine is an NMDAR antagonist and is proven effective in depression for the rapid and sustained antidepressant response, while rapastinel is an NMDAR positive...

Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.

Journal of Neurological Sciences 2022 Subha Subramanian, S. Haroutounian, Ben J Palanca et al. 58 citations

Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic...

Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.

Psychopharmacology 2022 Edem Ekpenyong Edem, Collins-Kevin Chukwudi Anyanwu, Kate Eberechukwu Nebo et al. 9 citations

Major depressive disorder (MDD) is a serious mental disorder with influence across the functional systems of the body. The pathogenesis of MDD has been known to involve the alteration of normal body functions responsible for the normal inflammation processes within the CNS; this along with other effects results in the depreciation of the sensorimotor performance of the body. Ketamine...

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.

Psychiatry Research 2022 Joshua D. Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues et al. 11 citations

Antidepressants are associated with symptomatic worsening in a subgroup of patients. Replicated evidence has demonstrated rapid and robust antidepressant effects with intravenous (IV) ketamine in treatment resistant depression (TRD); however, the risk of ketamine worsening depressive symptoms in a subgroup of patients remains unknown. Herein we report a retrospective analysis on the rates of...

Low-dose S-ketamine exerts antidepressant-like effects via enhanced hippocampal synaptic plasticity in postpartum depression rats.

Neurobiology of Stress 2022 Zhuoyu Ren, Mingling Wang, Mokhtar Aldhabi et al. 28 citations

Rapid antidepressant effects of S-ketamine have repeatedly been confirmed in patients with depression, as well as in chronic unpredictable mild stress (CUMS) animal models. However, the pharmacological study of S-ketamine for anti-postpartum depression has not been considered. In this study, the classical method of reproductive hormone withdrawal was used to construct a rat model of postpartum...

Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.

Frontiers in Psychiatry 2022 Ryan Yip, Jennifer Swainson, Atul Khullar et al. 13 citations

Ketamine is a versatile medication with an emerging role for the treatment of numerous psychiatric conditions, including treatment resistant depression. Current psychiatry guidelines for its intravenous administration to treat depression recommend regular blood pressure monitoring and an aggressive approach to potential transient hypertensive episodes induced by ketamine infusions. While this...

DOI: 10.3389/fpsyt.2022.1017504 (opens in new tab) Full text (opens in new tab) Hypertension Hypertensive emergency Ketamine infusion Treatment resistant depression